FDA
-
-
-
-
-
-
-
Candel Therapeutics secures $100M royalty funding deal with RTW
-
-
-
-
-
-
-
Candel Therapeutics to present phase 3 prostate cancer trial results at SITC
-
-
-
-
-
-
-
Trinity Capital Inc. Provides $130 Million in Growth Capital to Candel Therapeutics, Supporting Development of Viral Immunotherapies to Fight Cancer
-
-
-
-
-
-
-
Candel Therapeutics to present phase 3 prostate cancer data at ASTRO
-
-
-
-
-
-
-
Candel receives EMA orphan designation for pancreatic cancer drug
-
-
-
-
-
-
-
Candel Therapeutics (CADL) Announces $15 million Registered Direct Offering of Common Stock
-
-
-
-
-
-
-
Candel Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for CAN-2409 for the Treatment of Prostate Cancer
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

